Fields

Co-construction of tumor organoids with immune microenvironment, and evaluation of immune anti-tumor drug

Keypoints

1）Directly evaluate anti-tumor immune drugs at in vitro organ level;

2）Guide researchers to precisely develop anti-tumor immune drugs.

Contents

Co-culture of tumor organoids and immune microenvironment

1) Flow cytometry analysis of immune cell activation;

2) Flow cytometry and enzyme labeling to evaluate drug effects;

3) High-content microscopy to analyze tumor proliferation and apoptosis

4) Tumor organoid and immune microenvironment interaction expression profile analysis

5) High-throughput drug screening and evaluation of tumor organoid library.

Advancements

1) Realize single-factor simulation of tumor and immune microenvironment in vitro;

2) Organoid evaluation better reflects the real situation, which precisely guides researchers and reduce failures;

3) Provide experimental evidence for rapid expansion of drug trial syndrome

1、Driving a clinical phase I trial

2、Tumor organoid immunoconstruction

3、Immune checkpoint drug evaluation

4、NMPA encourages the application of organoids

NMPA Issues Technical Guidelines for Non-clinical Research and Evaluation of Gene Modified Cell Therapy Products (for Trial Implementation) 2021

 Technical Guidelines for Non-clinical Research and Evaluation of Gene Therapy Products (Draft for Public Comments) 2021

In 2021, CDE encourages employing organoids as non-clinical research models.

Co-construction of tumor organoids with immune microenvironment and evaluation of immunopharmaceuticals.

Related Keywords：

CAR-T ,TCR-T，oncolytic virus, solid tumor therapy, tumor immunotherapy evaluation, non-clinical drug evaluation

For more details, please contact：

400-600-8315